MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with
lower-risk myelodysplastic syndromes (
MDS) are to improve blood counts and alleviate symptoms. The
treatment options for lower-risk MDS discussed are:
recombinant erythropoietin,
lenalidomide,
immunosuppressive therapy, and
hypomethylating agents. They also discuss watchful waiting if a patient with lower-risk MDS has no symptoms or doesn’t have very low blood cell counts.
-
Share with family and friends:
Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.